season
influenza
epidem
result
million
case
around
million
death
year
worldwid
unit
state
peopl
hospit
annual
die
influenzarel
complic
cdc
diagnosi
influenza
b
clinic
manifest
alon
difficult
overlap
symptom
varieti
pathogen
includ
rhinoviru
arden
mackay
coronaviru
renoi
et
al
parainfluenza
viru
lau
et
al
respiratori
syncyti
viru
freymuth
et
al
adenoviru
lina
et
al
metapneumoviru
debur
et
al
enteroviru
lina
et
al
streptococcu
pyogen
yamada
et
al
use
antibiot
treat
upper
respiratori
tract
infect
without
proper
diagnosi
common
practic
unit
state
franck
smith
linder
et
al
instanc
nation
ambulatori
network
studi
upper
respiratori
tract
episod
identifi
receiv
antibiot
gill
et
al
although
respiratori
virus
respons
approxim
respiratori
infect
mahoni
use
antibiot
littl
benefit
viral
infect
play
major
role
develop
spread
antibioticresist
microorgan
substanti
increas
health
care
cost
thu
develop
rapid
costeffect
accur
screen
system
influenza
viru
avail
gener
popul
andor
local
physician
medic
treatment
facil
would
like
reduc
misus
antibiot
therapi
treatment
influenza
infect
rapid
identif
influenza
infect
would
reduc
transmiss
viru
includ
nosocomi
infect
allow
time
antivir
therapi
like
reduc
morbid
mortal
influenzarel
complic
therebi
lower
health
care
cost
current
sever
method
use
diagnos
influenza
b
includ
viral
cultur
later
flow
immunoassay
lfia
direct
fluoresc
antibodi
test
dfa
nucleic
acid
test
nat
diagnosi
influenza
b
viral
cultur
effect
labor
intens
time
consum
may
requir
highli
train
personnel
sever
day
provid
confirm
result
baladallasat
et
al
ruest
et
al
current
lfia
method
influenza
b
high
specif
cost
effect
result
acquir
within
min
unfortun
test
shown
exhibit
variabl
sensit
rang
low
louie
et
al
dfa
influenza
assay
demonstr
sensit
result
obtain
within
h
requir
high
level
technic
profici
perform
cultur
confirm
result
cram
et
al
nat
offer
high
sensit
specif
diagnosi
influenza
b
jenni
et
al
louie
et
al
pabbaraju
et
al
howev
use
nat
clinic
sector
may
prohibit
high
cost
delay
report
result
compar
lfia
dfa
lack
afford
near
pointofcar
sensit
specif
screen
system
influenza
viru
creat
void
address
lucigen
corp
middleton
wi
usa
design
firstgener
system
test
feasibl
nucleic
acid
later
flow
system
test
influenza
b
influenza
b
reagent
requir
use
nucleic
acid
later
flow
nalf
devic
detect
influenza
bamplifi
rna
molecul
nalf
devic
work
manner
analog
later
flow
immunoassay
visual
result
obtain
within
h
sampl
collect
allow
rapid
interpret
result
without
need
complex
expens
instrument
influenza
screen
reagent
could
altern
solut
rapid
influenza
b
test
clinic
sector
research
conduct
intern
review
boardapprov
protocol
allow
collect
clinic
sampl
patient
present
influenzalik
respiratori
symptom
emerg
depart
ed
brook
armi
medic
center
inform
consent
obtain
transfer
deidentifi
specimen
store
viru
case
novel
swine
flu
specimen
isol
viral
rna
local
epidemiolog
refer
laboratori
also
approv
twenti
nasal
swab
sampl
collect
ed
patient
influenzalik
symptom
archiv
deidentifi
streptococcu
pyogen
bacteri
specimen
deidentifi
specimen
transfer
local
epidemiolog
laboratori
investig
although
viral
sampl
obtain
epidemiolog
refer
laboratori
deidentifi
person
health
inform
person
identifi
remov
suppli
etiolog
agent
sampl
identifi
laboratori
personnel
perform
extract
luminex
rvp
assay
lucigen
pyroscript
test
blind
clinic
result
conclus
test
sampl
includ
novel
influenza
rna
specimen
influenza
season
influenza
season
influenza
b
season
adenoviru
parainfluenza
viral
specimen
neg
sampl
viru
detect
streptococcu
pyogen
cultureposit
throat
swab
sampl
confirm
via
polymeras
chain
reaction
pcr
specif
primer
ubiquit
pro
gene
describ
livezey
et
al
includ
studi
influenzaneg
control
sampl
store
object
preliminari
studi
assess
specif
sensit
influenza
b
nalf
system
potenti
rapid
screen
assay
system
simplic
independ
expens
complic
instrument
could
use
near
pointofcar
set
analysi
time
consid
includ
sampl
prepar
time
sinc
sampl
store
specimen
conveni
reproduc
purpos
well
comparison
food
drug
administr
approv
luminex
molecular
diagnost
toronto
ontario
canada
respiratori
viral
panel
rvp
test
nucleic
acid
isol
perform
autom
system
system
marci
letoil
franc
describ
bolotin
et
al
purifi
nucleic
acid
obtain
store
gold
standard
specif
sensit
assess
result
fda
approv
rvp
nucleic
acid
test
rvp
test
sensit
specif
studi
clinic
sampl
compar
dfa
cultur
result
mahoni
et
al
viral
isol
amplifi
hybrid
detect
instrument
luminex
austin
tx
use
xtag
rvp
kit
follow
vendor
protocol
briefli
purifi
nucleic
acid
sampl
revers
transcrib
multiplex
revers
transcript
polymeras
chain
reaction
rtpcr
tube
multiplex
target
specif
primer
extens
tspe
reaction
prepar
per
sampl
use
treat
rtpcr
tspe
reaction
product
reaction
ad
directli
microwel
contain
rvp
luminex
bead
mixtur
hybrid
phycoerythrin
report
ad
well
contain
hybrid
product
identifi
presenc
viru
assess
fluoresc
luminex
result
gener
analyz
use
softwar
compon
kit
tda
rvpi
addit
novel
rna
sampl
assay
microarray
techniqu
assay
combimatrix
corp
mukilteo
wa
usa
posit
identifi
sw
variant
straight
et
al
influenza
reagent
lucigen
test
sampl
studi
one
reaction
per
test
prepar
ice
pcr
tube
follow
nucleasefre
water
pyroscript
isotherm
master
mix
primer
mix
nucleic
acid
sampl
reaction
mix
centrifug
briefli
incub
min
thermal
cycler
eppendorf
hamburg
germani
preheat
reaction
stop
ice
pcr
tube
contain
specif
amplicon
load
cartridg
type
cassett
biohelix
corpor
beverli
usa
detect
accord
manufactur
instruct
influenza
bamplifi
molecul
enter
dna
strip
via
capillari
action
cassett
close
pcr
tube
releas
fluorescein
fam
biotinlabel
amplicon
flu
flu
b
reagent
detect
via
gold
nanoparticlelabel
antifam
antibodi
result
visual
read
min
photograph
result
record
ed
sampl
routin
test
use
rapid
antibodi
assay
binaxnow
aler
waltham
usa
dfa
viral
cultur
bamc
clinic
laboratori
data
shown
season
influenza
sampl
previous
identifi
local
epidemiolog
laboratori
influenza
subtyp
respect
per
standard
protocol
data
shown
influenza
b
sampl
similarli
identifi
epidemiolog
laboratori
influenza
season
viral
sampl
confirm
luminex
rvp
assay
influenza
similarli
influenza
season
viral
isol
confirm
influenza
rvp
assay
two
addit
sampl
collect
bamc
ed
identifi
rvp
influenza
nosubtyp
classifi
novel
influenza
although
confirm
pcr
microarray
six
ed
sampl
identifi
luminex
rvp
assay
posit
viru
influenza
nosubtyp
discuss
rhinoviru
parainfluenza
metapneumoviru
addit
influenza
b
adenoviru
parainfluenza
sampl
epidemiolog
laboratori
also
confirm
luminex
rvp
assay
fourteen
ed
sampl
plu
sampl
epidemiolog
laboratori
viru
detect
streptococcu
pyogen
bacteri
sampl
use
neg
control
influenza
influenza
b
calcul
see
tabl
total
falseposit
posit
lucigen
system
neg
gold
standard
luminex
rvp
assay
influenza
falseposit
influenza
b
result
observ
pyroscript
influenza
test
case
influenza
sampl
identifi
rvp
assay
influenza
consid
true
neg
calcul
influenza
specif
convers
sampl
identifi
rvp
assay
influenza
b
consid
true
influenza
b
neg
thu
specif
pyroscript
influenza
reagent
influenza
influenza
b
test
recent
influenza
pandem
caus
million
human
case
novel
influenza
approxim
hospit
death
unit
state
alon
april
decemb
accord
estim
center
diseas
control
prevent
cdc
develop
easytous
costeffect
reliabl
new
diagnost
method
access
primari
health
care
provid
screen
patient
need
rapid
detect
influenza
influenza
b
rapid
screen
influenza
primari
health
care
facil
would
aid
sequest
infect
patient
gener
popul
limit
transmiss
would
reduc
unnecessari
use
antibiot
provid
influenza
patient
misdiagnos
bacteri
respiratori
ill
pyroscript
influenza
reagent
combin
cartridg
type
cassett
test
studi
demonstr
excel
outcom
paramet
greater
specif
sensit
influenza
b
test
similar
isotherm
amplif
test
combin
type
cassett
develop
use
rapidli
detect
pathogen
microorgan
includ
herp
simplex
viru
type
kim
et
al
mycobacterium
tuberculosi
motr
et
al
human
immunodefici
viru
tang
et
al
toxigen
clostridium
difficil
chow
et
al
novel
influenza
sampl
initi
identifi
rvp
epidemiolog
laboratori
influenza
nosubtyp
novel
influenza
detect
rvp
assay
influenza
nosubtyp
due
recognit
matrix
gene
combin
lack
detect
either
season
target
gene
investig
report
influenza
season
influenza
nosubtyp
case
detect
rpv
test
like
novel
influenza
ginocchio
st
georg
vinikoor
et
al
sampl
confirm
via
rtpcr
novel
influenza
data
shown
prior
receiv
bamc
rna
sampl
test
bamc
confirm
influenza
sw
variant
straight
et
al
novel
influenza
sw
rna
sampl
detect
microarray
techniqu
also
reevalu
luminex
rvp
assay
viral
etiolog
could
identifi
therefor
sampl
elimin
studi
extract
nucleic
acid
detect
influenza
viru
autom
robot
system
use
investig
belongia
et
al
bolotin
et
al
bose
et
al
yang
et
al
done
studi
use
system
system
requir
least
h
extract
nucleic
acid
clinic
sampl
includ
sampl
prepar
time
viralbacteri
lysi
time
autom
nucleic
acid
extract
system
excel
instrument
use
refer
laboratori
larger
number
sampl
process
bulki
expens
use
small
laboratori
physician
offic
altern
nucleic
acid
extract
method
must
incorpor
futur
pyroscript
influenza
screen
system
fulfil
time
effici
requir
rapid
screen
assay
addit
requir
screen
influenza
b
separ
test
pyroscript
influenza
system
requir
reaction
differ
reagent
detect
cassett
ideal
futur
version
pyroscript
influenza
screen
system
also
allow
simultan
screen
virus
might
includ
respiratori
viru
target
object
studi
determin
sensit
specif
pyroscript
influenza
system
loss
sensit
occur
test
assay
produc
posit
result
gold
standard
assay
determin
posit
influenza
influenza
b
sensit
result
failur
identifi
rvpposit
sampl
posit
pyroscript
assay
could
sever
reason
pyroscript
abl
identifi
true
posit
one
possibl
could
due
store
rna
deterior
time
sinc
insuffici
sampl
remain
addit
retest
rvp
assay
possibl
exclud
novel
season
influenza
season
influenza
b
sampl
appear
fals
neg
could
longterm
storageinduc
rna
degrad
andor
freezethaw
cycl
botl
et
al
ginocchio
et
al
loss
specif
occur
due
falseposit
result
posit
pyroscript
assay
rvp
studi
total
fals
posit
observ
one
possibl
falseposit
result
could
primer
rvp
pyroscript
assay
ident
addit
possibl
may
mutat
viral
genom
rvp
primersprob
bind
affect
isotherm
amplif
employ
pyroscript
test
anoth
possibl
could
nonspecif
amplif
pyroscript
assay
conclus
pyroscript
influenza
reagent
combin
cartridg
type
cassett
selfcontain
dispos
detect
devic
requir
special
instrument
complic
specimen
handl
obtain
visual
result
within
h
nucleic
acid
isol
pyroscript
influenza
b
test
studi
show
potenti
fill
screen
void
rapid
influenza
diagnosi
futur
develop
pyroscript
influenza
reagent
screen
system
implement
altern
nucleic
acid
extract
method
provid
true
pointofcar
nat
human
influenza
diagnost
warrant
